%	O
%	O
TITLE	O

HPV	O
DNA	O
,	O
E6	O
/	O
E7	O
mRNA	O
,	O
and	O
p16INK4a	O
detection	O
in	O
head	O
and	O
neck	O
cancers	O
:	O
a	O
systematic	B-Study_Type
review	I-Study_Type
and	I-Study_Type
meta	I-Study_Type
-	I-Study_Type
analysis	I-Study_Type
.	O

%	O
%	O
ABSTRACT	O

We	O
aimed	O
to	O
provide	O
updated	O
information	O
about	O
the	O
global	O
estimates	O
of	O
attributable	O
fraction	O
and	O
type	O
distribution	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
by	O
doing	O
a	O
systematic	B-Study_Type
review	I-Study_Type
and	I-Study_Type
meta	I-Study_Type
-	I-Study_Type
analysis	I-Study_Type
.	O
We	O
did	O
a	O
literature	O
search	O
on	O
PubMed	O
to	O
identify	O
studies	O
that	O
used	O
PCR	B-HPV_Lab_Technique
for	O
detection	O
of	O
HPV	O
DNA	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
with	O
information	O
about	O
HPV	O
genotype	O
distribution	O
.	O

We	O
included	O
studies	O
that	O
tested	O
20	O
or	O
more	O
biopsies	O
per	O
cancer	O
site	O
and	O
were	O
published	O
between	O
July	B-Study_Time
15	I-Study_Time
,	I-Study_Time
1990	I-Study_Time
,	I-Study_Time
and	I-Study_Time
Feb	I-Study_Time
29	I-Study_Time
,	I-Study_Time
2012	I-Study_Time
.	O

We	O
collected	O
information	O
about	O
sex	O
,	O
risk	O
factors	O
,	O
HPV	O
detection	O
methods	O
,	O
and	O
biomarkers	O
of	O
potentially	O
HPV	O
-	O
induced	O
carcinogenesis	O
(	O
E6	O
/	O
E7	O
mRNA	O
and	O
p16	O
(	O
INK4a	O
)	O
)	O
.	O

If	O
it	O
was	O
not	O
possible	O
to	O
abstract	O
the	O
required	O
information	O
directly	O
from	O
the	O
paper	O
,	O
we	O
contacted	O
the	O
authors	O
.	O

We	O
did	O
a	O
meta	B-Study_Type
-	I-Study_Type
analysis	I-Study_Type
to	O
produce	O
pooled	O
prevalence	B-Incidence_or_Prevalence
estimates	O
including	O
a	O
meta	O
-	O
regression	O
to	O
explore	O
sources	O
of	O
heterogeneity	O
.	O
148	B-Study_Cohort
studies	I-Study_Cohort
were	I-Study_Cohort
included	I-Study_Cohort
,	I-Study_Cohort
contributing	O
data	O
for	O
12â€ˆ163	O
cases	O
of	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
from	O
44	O
countries	O
.	O

HPV	O
DNA	O
was	O
detected	O
in	O
3837	O
cases	O
.	O

HPV16	O
accounted	O
for	O
82Â·2	O
%	O
(	O
95	O
%	O
CI	O
77Â·7	O
-	O
86Â·4	O
)	O
of	O
all	O
HPV	O
DNA	O
positive	O
cases	O
.	O

By	O
cancer	O
site	O
,	O
pooled	O
HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
estimates	O
were	O
45Â·8	O
%	O
(	O
95	O
%	O
CI	O
38Â·9	O
-	O
52Â·9	O
)	O
for	O
oropharynx	O
,	O
22Â·1	O
%	O
(	O
16Â·4	O
-	O
28Â·3	O
)	O
for	O
larynx	O
(	O
including	O
hypopharynx	O
)	O
,	O
and	O
24Â·2	O
%	O
(	O
18Â·7	O
-	O
30Â·2	O
)	O
for	O
oral	O
cavity	O
.	O

The	O
percent	O
positivity	O
of	O
p16	O
(	O
INK4a	O
)	O
positive	O
cases	O
in	O
HPV	O
-	O
positive	O
oropharyngeal	O
cancer	O
cases	O
was	O
86Â·7	O
%	O
(	O
95	O
%	O
CI	O
79Â·2	O
-	O
92Â·9	O
)	O
and	O
of	O
E6	O
/	O
E7	O
mRNA	O
positive	O
cases	O
was	O
86Â·9	O
%	O
(	O
73Â·2	O
-	O
96Â·8	O
)	O
.	O

The	O
estimate	O
of	O
HPV	O
attributable	O
fraction	O
in	O
oropharyngeal	O
cancer	O
defined	O
by	O
expression	O
of	O
positive	O
cases	O
of	O
E6	O
/	O
E7	O
mRNA	O
was	O
39Â·8	O
%	O
and	O
of	O
p16	O
(	O
INK4a	O
)	O
was	O
39Â·7	O
%	O
.	O

Of	O
subsites	O
,	O
tonsils	O
(	O
53Â·9	O
%	O
,	O
95	O
%	O
CI	O
46Â·4	O
-	O
61Â·3	O
)	O
had	O
the	O
highest	O
HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
.	O

HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
varied	O
significantly	O
by	O
anatomical	O
site	O
,	O
geographic	O
region	O
,	O
but	O
not	O
by	O
sex	O
or	O
tobacco	O
or	O
alcohol	O
consumption	O
.	O
The	O
contribution	O
of	O
HPV	O
prevalence	B-Incidence_or_Prevalence
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
and	O
in	O
particular	O
that	O
of	O
HPV16	O
in	O
the	O
oropharynx	O
shows	O
the	O
potential	O
benefit	O
of	O
prophylactic	O
vaccines	O
.	O

European	O
Commission	O
.	O

%	O
%	O
METHODS	O

Search	O
stratedy	O
and	O
selection	O
criteria	O

CN	O
and	O
MM	O
independently	O
searched	O
the	O
National	O
Institutes	O
of	O
Health	O
PubMed	O
electronic	O
databases	O
for	O
relevant	O
studies	O
on	O
the	O
prevalence	B-Incidence_or_Prevalence
of	O
HPV	O
DNA	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinoma	O
using	O
the	O
following	O
MeSH	O
terms	O
:	O
“papillomaviridae”	O
and	O
“head	O
and	O
neck	O
neoplasms”	O
in	O
combination	O
with	O
keywords	O
“polymerase	O
chain	B-HPV_Lab_Technique
reaction”	I-HPV_Lab_Technique
or	I-HPV_Lab_Technique
“PCR”	O
,	O
published	O
between	O
Feb	B-Study_Time
1	I-Study_Time
,	I-Study_Time
2004	I-Study_Time
,	I-Study_Time
and	I-Study_Time
Feb	I-Study_Time
29	I-Study_Time
,	I-Study_Time
2012	I-Study_Time
.	I-Study_Time

We	O
also	O
included	O
all	O
papers	O
selected	O
in	O
Kreimer	O
and	O
colleagues’	O
systematic	O
review9	O
(	O
published	O
from	O
July	O
15	O
,	O
1990	O
to	O
Feb	O
20	O
,	O
2004	O
)	O
.	O

MOOSE	O
guidelines	O
and	O
the	O
PRISMA	O
statement	O
were	O
consulted	O
to	O
conduct	O
the	O
search	O
.	O
13	O
,	O
14	O
We	O
also	O
reviewed	O
reference	O
lists	O
of	O
included	O
studies	O
to	O
identify	O
additional	O
articles	O
.	O

Study	O
selection	O
and	O
data	O
extraction	O

CN	O
,	O
MM	O
,	O
and	O
LA	O
independently	O
assessed	O
the	O
studies	O
for	O
inclusion	O
in	O
the	O
review	O
.	O

All	O
articles	O
reporting	O
data	O
for	O
HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
and	O
type	O
distribution	O
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
since	O
Aug	O
15	O
,	O
1990	O
,	O
were	O

selected	O
.	O

An	O
eﬀort	O
was	O
made	O
to	O
exclude	O
redundant	O
articles	O
including	O
the	O
same	O
population	O
from	O
the	O
ﬁnal	O
analysis	O
.	O

If	O
articles	O
from	O
the	O
same	O
cohort	O
were	O
retrieved	O
,	O
the	O
article	O
analysing	O
the	O
largest	O
sample	O
was	O
selected	O
.	O

For	O
studies	O
involving	O
more	O
than	O
one	O
geographic	O
location	O
,	O
the	O
data	O
were	O
divided	O
into	O
components	O
from	O
each	O
continent	O
if	O
possible	O
.	O

We	O
included	O
studies	O
if	O
they	O
had	O
HPV	O
information	O
about	O
at	O
least	O
one	O
of	O
the	O
following	O
cancer	O
sites	O
or	O
subsites	O
:	O
oral	O
cavity	O
,	O
oropharynx	O
,	O
hypopharynx	O
,	O
and	O
larynx	O
;	O
a	O
minimum	O
of	O
20	O
site	O
-	O
speciﬁc	O
cases	O
tested	O
for	O
HPV	O
(	O
for	O
this	O
criteria	O
hypopharynx	O
and	O
larynx	O
cases	O
were	O
combined	O
)	O
;	O
a	O
clear	O
description	O
of	O
DNA	O
PCR	B-HPV_Lab_Technique
-	O
based	O
testing	O
methods	O
;	O
identiﬁcation	O
of	O
the	O
histological	O
classiﬁcation	O
as	O
squamous	O
cell	O
carcinoma	O
;	O
primary	O
tumour	O
;	O
and	O
diagnosis	O
of	O
a	O
tumour	O
conﬁned	O
in	O
only	O
one	O
site	O
.	O

We	O
excluded	O
carcinomas	O
in	O
situ	O
and	O
nasopharyngeal	O
carcinomas	O
.	O

Unless	O
otherwise	O
speciﬁed	O
,	O
we	O
assumed	O
that	O
all	O
cases	O
were	O
primary	O
.	O

We	O
further	O
excluded	O
recurrent	O
cases	O
and	O
purposively	O
selected	O
cases—eg	O
,	O
only	O
stage	O
III	O
/	O
IV	O
.	O

Head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
(	O
with	O
their	O
associated	O
International	O
Classiﬁcation	O
of	O
Diseases	O
-	O
10	O
code	O
)	O
were	O
classiﬁed	O
as	O
follows	O
:	O
oral	O
cavity	O
:	O
anterior	O
two	O
-	O
thirds	O
of	O
the	O
tongue	O
(	O
C02	O
.	O
0–3	O
,	O
C02	O
.	O
5–9	O
)	O
,	O
tongue	O
unspeciﬁed	O
(	O
C02	O
.	O
9	O
)	O
,	O
lip	O
(	O
C00	O
.	O
0	O
-	O
9	O
)	O
,	O
gum	O
(	O
C03	O
.	O
0–9	O
)	O
,	O
ﬂoor	O
of	O
the	O
mouth	O
(	O
C04	O
.	O
0	O
-	O
9	O
)	O
,	O
hard	O
palate	O
(	O
C05	O
.	O
0	O
)	O
,	O
palate	O
unspeciﬁed	O
(	O
C05	O
.	O
9	O
)	O
,	O
other	O
oral	O
cavity—including	O
buccal	O
mucosa	O
and	O
retromolar	O
area	O
(	O
C06	O
.	O
0–8	O
)	O
,	O
oral	O
cavity	O
unspeciﬁed	O
(	O
C06	O
.	O
9	O
)	O
;	O
oropharynx	O
:	O
base	O
of	O
the	O
tongue	O
(	O
C01	O
)	O
,	O
soft	O
palate	O
(	O
C05	O
.	O
1	O
)	O
,	O

tonsil	O
(	O
C02	O
.	O
4	O
,	O
C09	O
.	O
0–9	O
)	O
,	O
uvula	O
(	O
C05	O
.	O
2	O
)	O
,	O
other	O
parts	O
of	O
the	O
oropharynx	O
(	O
C10	O
.	O
0	O
-	O
9	O
)	O
,	O
Waldeyer’s	O
ring	O
(	O
C14	O
.	O
2	O
)	O
,	O
and	O
oropharynx	O
unspeciﬁed	O
(	O
C10	O
.	O
9	O
)	O
;	O
or	O
larynx	O
:	O
glottis	O
(	O
C32	O
.	O
0	O
)	O
,	O
supraglottis	O
(	O
C32	O
.	O
1	O
)	O
,	O
subglottis	O
(	O
C32	O
.	O
2	O
)	O
,	O
other	O
and	O
unspeciﬁed	O
larynx	O
subsites	O
(	O
C32	O
.	O
3–9	O
)	O
.	O

Hypopharynx	O
cases	O
(	O
C13	O
)	O
were	O
classiﬁed	O
as	O
belonging	O
to	O
the	O
larynx	O
,	O
including	O
pyriform	O
sinus	O
(	O
C12	O
)	O
.	O

Tongue	O
and	O
palate	O
unspeciﬁed	O
cases	O
were	O
classiﬁed	O
as	O
belonging	O
to	O
the	O
oral	O
cavity	O
.	O

Maxilla	O
,	O
mandible	O
,	O
other	O
bone	O
,	O
and	O
cheek	O
non	O
-	O
mucosal	O
sites	O
were	O
excluded	O
.	O

MM	O
,	O
LL	O
,	O
and	O
LA	O
extracted	O
the	O
data	O
and	O
CN	O
and	O
LA	O
cross	O
-	O
checked	O
the	O
data	O
extraction	O
.	O

CN	O
,	O
LA	O
,	O
and	O
MM	O
reviewed	O
and	O
solved	O
discrepancies	O
by	O
consensus	O
.	O

The	O
variables	O
collected	O
speciﬁcally	O
for	O
all	O
anatomical	O
sites	O
when	O
available	O
included	O
:	O
ﬁrst	O
author	O
,	O
publication	O
year	O
,	O
journal	O
of	O
publication	O
,	O
study	O
country	O
,	O
study	O
population	O
,	O
case	O
selection	O
methods	O
,	O
study	O
period	O
,	O
mean	O
age	O
of	O
study	O
population	O
,	O
sex	O
distribution	O
,	O
tobacco	O
smoking	O
(	O
ever	O
/	O
never	O
)	O
and	O
alcohol	O
consumption	O
(	O
ever	O
/	O
never	O
)	O
,	O
method	O
of	O
specimen	B-HPV_Sample_Type
preservation	O
,	O
additional	O
biomarkers	O
other	O
than	O
HPV	O
DNA	O
detection	O
,	O
number	O
of	O
controls	O
for	O
contamination	O
items	O
mentioned	O
in	O
the	O
paper	O
,	O
primers	O
used	O
for	O
HPV	B-HPV_Lab_Technique
DNA	I-HPV_Lab_Technique

PCR	I-HPV_Lab_Technique
testing	I-HPV_Lab_Technique
and	O
genotyping	O
method	O
,	O
and	O
length	O
of	O
the	O
amplicon	O
used	O
in	O
the	O
PCR	B-HPV_Lab_Technique
(	O
taking	O
HPV16	O
as	O
a	O
reference	O
)	O
.	O

Whenever	O
the	O
length	O
of	O
the	O
amplicon	O
was	O
not	O
directly	O
reported	O
in	O
the	O
paper	O
,	O
it	O
was	O
calculated	O
with	O
the	O
HPV16	O
gene	O
sequence	O
and	O
the	O
forward	O
and	O
reverse	O
primers	O
obtained	O
from	O
the	O
papers	O
.	O

When	O
the	O
information	O
was	O
not	O
available	O
,	O
the	O
technique	O
was	O
classiﬁed	O
as	O
unspeciﬁed	O
.	O

In	O
cases	O
for	O
which	O
more	O
than	O
one	O
type	O
-	O
speciﬁc	O
primer	O
was	O
used	O
,	O
the	O
shorter	O
amplicon	O
taking	O
into	O
account	O
HPV16	O
as	O
a	O
reference	O
was	O
reported	O
.	O

Other	O
variables	O
collected	O
were	O
cancer	O
site	O
and	O
subsite	O
,	O
site	O
-	O
speciﬁc	O
sample	B-HPV_Sample_Type
size	O
and	O
number	O
of	O
HPV	O
-	O
positive	O
samples	B-HPV_Sample_Type
,	I-HPV_Sample_Type
site	O
-	O
speciﬁc	O
number	O
of	O
HPV	O
types	O
detected	O
,	O
and	O
number	O
of	O
multiple	O
infections	O
.	O

Data	O
were	O
collected	O
for	O
all	O
detectable	O
HPV	O
types	O
.	O

The	O
papers	O
were	O
assessed	O
for	O
quality	O
through	O
collection	O
of	O
eight	O
quality	O
criteria	O
:	O
use	O
of	O
broad	O
spectrum	O
PCR	B-HPV_Lab_Technique
,	O
use	O
of	O
human	O
gene	O
marker	O
,	O
whether	O
the	O
cases	O
were	O
histologically	O
conﬁrmed	O
,	O
control	O
for	O
contamination	O
mentioned	O
in	O
the	O
paper	O
,	O
whether	O
the	O
paper	O
contained	O
speciﬁc	O
information	O
about	O
age	O
and	O
sex	O
,	O
whether	O
the	O
recruitment	O
period	O
was	O
stated	O
,	O
whether	O
sample	O
size	O
was	O
at	O
least	O
50	O
cases	O
,	O
and	O
whether	O
the	O
cases	O
were	O
recruited	O
randomly	O
or	O
consecutively	O
or	O
were	O
incident	O
cases	O
.	O

The	O
quality	O
score	O
of	O
all	O
papers	O
was	O
calculated	O
as	O
the	O
sum	O
of	O
the	O
result	O
(	O
0=no	O
/	O
1=yes	O
)	O
for	O
all	O
quality	O
control	O
items	O
.	O

A	O
new	O
variable	O
was	O
created	O
,	O
HPV	O
group	O
,	O
in	O
which	O
the	O
diﬀerent	O
cancer	O
sites	O
or	O
subsites	O
were	O
classiﬁed	O
in	O
view	O
of	O
their	O
association	O
with	O
HPV	O
according	O
to	O
the	O
existing	O
evidence	O
:	O
15	O
,	O
16	O
HPV	O
group	O
0	O
(	O
weak	O
association	O
with	O
HPV	O
)	O
:	O
oral	O
cavity	O
without	O
subsite	O
speciﬁcation	O
,	O
lip	O
,	O
ﬂoor	O
of	O
the	O
mouth	O
,	O
hard	O
palate	O
,	O
gum	O
,	O
other	O
oral	O
cavity	O
,	O
larynx	O
,	O
and	O
hypopharynx	O
without	O
subsite	O
speciﬁcation	O
,	O
glottis	O
,	O
supraglottis	O
,	O
subglottis	O
,	O
and	O
pyriform	O
sinus	O
;	O
HPV	O
group	O
1	O
(	O
moderate	O
association	O
with	O
HPV	O
)	O
:	O
tongue	O
and	O
palate	O
unspeciﬁed	O
;	O

or	O
HPV	O
group	O
2	O
(	O
strong	O
association	O
with	O
HPV	O
)	O
:	O
oropharynx	O
without	O
subsite	O
speciﬁcation	O
,	O
tonsil	O
,	O
soft	O
palate	O
,	O
base	O
of	O
the	O
tongue	O
,	O
and	O
other	O
parts	O
of	O
the	O
oropharynx	O
.	O

If	O
it	O
was	O
not	O
possible	O
to	O
extract	O
the	O
required	O
information	O
directly	O
from	O
the	O
paper	O
,	O
authors	O
were	O
contacted	O
a	O
maximum	O
of	O
three	O
times	O
to	O
provide	O
clariﬁcations	O
or	O
additional	O
information	O
.	O

Two	O
additional	O
datasets	O
were	O
also	O
prepared	O
,	O
one	O
with	O
information	O
about	O
HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
and	O
type	O
distribution	O
stratiﬁed	O
by	O
sex	O
and	O
another	O
with	O
information	O
about	O
additional	O
biomarkers	O
E6	O
/	O
E7	O
mRNA	O
and	O
p16INK4a	O
.	O

The	O
variables	O
collected	O
speciﬁcally	O
for	O
the	O
ﬁnal	O
dataset	O
were	O
type	O
of	O
cases	O
tested	O
for	O
additional	O
biomarkers	O
,	O
number	O
of	O
HPV	O
DNA	O
positive	O
cases	O
tested	O
for	O
p16INK4a	O
,	O
E6	O
/	O
E7	O
mRNA	O
,	O
or	O
both	O
,	O
antibody	O
and	O
staining	O
cutoﬀs	O
used	O
in	O
the	O
p16INK4a	O
assay	O
,	O
techniques	O
used	O
for	O
the	O
E6	O
/	O
E7	O
mRNA	O
assay	O
,	O
and	O
number	O
of	O
HPV	O
DNA	O
positive	O
cases	O
additionally	O
positive	O
for	O
p16INK4a	O
or	O
E6	O
/	O
E7	O
mRNA	O
.	O

Statistical	O
analysis	O

HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
was	O
computed	O
by	O
dividing	O
the	O
number	O
of	O
HPV	O
DNA	O
positive	O
cases	O
by	O
the	O
total	O
number	O
of	O
cases	O
tested	O
.	O

HPV	O
DNA	O
type	O
-	O
speciﬁc	O
prevalence	B-Incidence_or_Prevalence
was	O
calculated	O
by	O
dividing	O
the	O
number	O
of	O
cases	O
positive	O
for	O
a	O
speciﬁc	O
type	O
(	O
present	O
in	O
either	O
single	O
or	O
multiple	O
infections	O
)	O
by	O
the	O
total	O
number	O
of	O
cases	O
tested	O
for	O
that	O
type	O
.	O

HPV	O
DNA	O
type	O
-	O
speciﬁc	O
relative	O
contribution	O
was	O
calculated	O
by	O
dividing	O
the	O
number	O
of	O
cases	O
positive	O
for	O
a	O

speciﬁc	O
type	O
(	O
present	O
in	O
either	O
single	O
or	O
multiple	O
infections	O
)	O
by	O
the	O
total	O
number	O
of	O
HPV	O
DNA	O
positive	O
cases	O
tested	O
for	O
the	O
speciﬁc	O
type	O
.	O

To	O
pool	O
prevalences	B-Incidence_or_Prevalence
and	O
relative	O
contributions	O
,	O
we	O
used	O
metaprop	O
,	O
statistical	O
procedure	O
in	O
STATA	O
(	O
version	O
10	O
.	O
1	O
)	O
,	O
developed	O
at	O
the	O
Unit	O
Cancer	O
Epidemiology	O
(	O
IPH	O
,	O
Brussels	O
)	O
.	O
17	O
,	O
18	O
A	O
random	O
eﬀects	O
model	O
including	O
Freeman	O
-	O
Tukey	O
arcsine	O
transformation	O
of	O
the	O
prevalence	B-Incidence_or_Prevalence
was	O
used	O
to	O
normalise	O
variance	O
.	O

95	O
%	O
CIs	O
were	O
computed	O
around	O
study	O
-	O
speciﬁc	O
and	O
pooled	O
prevalences	B-Incidence_or_Prevalence
based	O
on	O
the	O
score	O
-	O
test	O
statistic	O
.	O

Interstudy	O
heterogeneity	O
was	O
assessed	O
with	O
Cochran’s	O
Q	O
-	O
test	O
.	O
19	O
The	O
percentage	O
of	O
total	O
variation	O
across	O
studies	O
because	O
of	O
heterogeneity	O
was	O
evaluated	O
with	O
the	O
I²	O
measure	O
.	O
20	O
Prevalences	B-Incidence_or_Prevalence
were	O
pooled	O
by	O
anatomical	O
site	O
,	O
available	O
subsites	O
,	O
worldwide	O
,	O
and	O
by	O
geographical	O
region	O
and	O
sample	O
size	O
.	O

Relative	O
risks	O
(	O
RR	O
)	O
for	O
overall	O
HPV	O
DNA	O
and	O
HPV16	O
DNA	O
prevalence	B-Study_Location
in	O
men	O
compared	O
with	O
in	O
women	O
were	O
pooled	O
with	O
metan	O
in	O
STATA	O
(	O
version	O
10	O
.	O
1	O
)	O
.	O
21	O

Pooled	O
p16INK4a	O
and	O
E6	O
/	O
E7	O
mRNA	O
percent	O
positivities	O
were	O
computed	O
with	O
metaprop	O
command	O
.	O
17	O
,	O
18	O
p16INK4a	O
and	O
E6	O
/	O
E7	O
mRNA	O
percent	O
positivities	O
refer	O
to	O
the	O
percentage	O
of	O
HPV	O
DNA	O
positive	O
samples	B-HPV_Sample_Type
that	O
were	O
also	O
positive	O
for	O
p16INK4a	O
or	O
E6	O
/	O
E7	O
mRNA	O
in	O
relation	O
to	O
all	O
the	O
HPV	O
DNA	O
positive	O
samples	B-HPV_Sample_Type
tested	O
for	O
the	O
speciﬁc	O
biomarker	O
.	O

Subgroup	O
meta	O
-	O
analysis	O
was	O
done	O
for	O
the	O
proportion	O
of	O
p16INK4a	O
positivity	O
by	O
staining	O
cutoﬀs	O
and	O
type	O
of	O
selection	O
of	O
patients	O
with	O
oropharyngeal	O
cancer	O
.	O

The	O
HPV	O
attributable	O
fraction	O
was	O
computed	O
as	O
the	O
product	O
of	O
the	O
HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
and	O
the	O
percent	O
positivities	O
of	O
the	O
biomarker	O
in	O
HPV	O
-	O
positive	O
cases	O
.	O

The	O
eﬀect	O
of	O
covariates	O
on	O
HPV	O
DNA	O
prevalence	B-Incidence_or_Prevalence
in	O
head	O
and	O
neck	O
squamous	O
cell	O
carcinomas	O
was	O
explored	O
with	O
meta	O
-	O
regression	O
.	O
22	O
The	O
covariates	O
were	O
study	O
country	O
;	O
geographical	O
region	O
;	O
age	O
;	O
proportion	O
of	O
men	O
;	O
proportion	O
of	O
ever	O
-	O
smokers	O
;	O
proportion	O
of	O
ever	O
-	O
drinkers	O
of	O
alcohol	O
;	O
start	O
,	O
middle	O
,	O
and	O
end	O
year	O
of	O
the	O
study	O
period	O
;	O
method	O
of	O
specimen	B-HPV_Sample_Type
preservation	O
;	O
number	O
of	O
items	O
mentioned	O
related	O
to	O
control	O
of	O
contamination	O
;	O
primers	O
used	O
for	O
HPV	O
DNA	O
ampliﬁcation	O
;	O
length	O
of	O
the	O
amplicon	O
target	O
of	O
the	O
PCR	B-HPV_Lab_Technique
;	O
the	O

eight	O
quality	O
control	O
measures	O
,	O
and	O
the	O
overall	O
quality	O
score	O
.	O

Only	O
the	O
covariates	O
identiﬁed	O
to	O
be	O
statistically	O
signiﬁcant	O
(	O
p	O
<	O
0·05	O
)	O
in	O
a	O
ﬁrst	O
-	O
step	O
bivariate	O
analysis	O
were	O
included	O
in	O
the	O
multivariate	O
models	O
.	O

Role	O
of	O
the	O
funding	O
source	O

The	O
funder	O
of	O
the	O
study	O
had	O
no	O
role	O
in	O
the	O
study	O
design	O
,	O
data	O
collection	O
,	O
data	O
analysis	O
,	O
data	O
interpretation	O
,	O
or	O
writing	O
of	O
the	O
report	O
.	O

All	O
authors	O
had	O
full	O
access	O
to	O
all	O
the	O
data	O
in	O
the	O
study	O
and	O
had	O
ﬁnal	O
responsibility	O
for	O
the	O
decision	O
to	O
submit	O
for	O
publication	O
.	O

